engleski

The evaluation of the tumor marker CYFRA 21-1 in the differentiation of malignant and benign pulmonary lesions

Cytokeratin marker CYFRA 21-1 has proven itself as a useful tool in prognosis, therapy and detection of relapse in our clinical research. In this paper we will show its usefulness in differential diagnosis in 254 patients with nodose pulmonary lesion. In 37.40% we found benign pulmonary diseases, while in 37.80% we found metastases (colon, larynx, kidney, etc.). 24.8% of our patients were diagnostically no verified. The value of cytokeratin marker CYFRA 21-1 was determined by Boehringe Manheim immunoenzymatic method. All first group patients has values under the cut off value according to Roche Diagnostics, while in second group 82.73% did not reach the same value. Both of these groups were surgically treated and PHD approved the diagnosis. The third group was surgically treated after the two months period during which CYFRA 21-1 was determined. In 69.84% of the third group the values increased compared to the start value for 1ng/ml. After the surgical treatment PHD revealed primary lung tumors in 44 patients, metastasis in 9, and benign disease in 10 patients. These results strongly suggest the application of cytokeratin marker CYFRA 21-1 in monitoring of pulmonary lesion patients.

Tumor marker; Lung cancer; Cyfra 21-1

ATS = American Thoracic Society